Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies

Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience

F. Rampp (Munich, Germany), H. Popper (Graz, Austria), J. Meyer (Munich, Germany)

Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside

Session: Immune-mediated interstitial lung diseases: from bench to bedside
Session type: Thematic Poster
Number: 1366

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Rampp (Munich, Germany), H. Popper (Graz, Austria), J. Meyer (Munich, Germany). Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience. 1366

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021
Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017
A Comparison of Pulmonary Rehabilitation Outcomes in Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019
Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020
Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021
Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019
Risk Factor for Chronic Obstructive Pulmonary Disease in Never-Smoker Patients with Non-Cystic Fibrosis Bronchiectasis Source: International Congress 2019 – Bronchiectasis Year: 2019
Associated Factors with the Approval of Pulmonary Rehabilitation for Inpatients with Interstitial Lung Disease: Two-center Retrospective Study Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018
Effect of Antifibrotic Therapies in Patients with Interstitial Pneumonia with Autoimmune Features Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020
A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021
Risk Factors for Mortality in Patients with Idiopathic Pulmonary Fibrosis Followed at Intensive Care Unit due to Acute Respiratory Failure Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018
Does a Tailored Intervention to Promote Adherence in Patients with Chronic Lung Disease Affect Exacerbations? Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019
Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019
Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018
Utility of Lung Ultrasound in Interstitial Lung Disease - A Paradigm Shift Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020
Advance Care Planning in Patients with Chronic Obstructive Pulmonary Disease assessed for Long Term Oxygen Therapy Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018
Study to Evaluate Satisfaction with the Inhalation Device Used by Patients with Asthma or Chronic Obstructive Pulmonary Disease and the Association with Adherence and Disease Control Source: Virtual Congress 2020 – Novel insights into nursing interventions for managing patients with asthma and COPD Year: 2020
The Use of Respiratory Sounds for Automated Detection of Obstructive Pulmonary Disease: Do Lung Sound Labels Provide Value? Source: International Congress 2017 – Lung function testing in different patient categories Year: 2017
Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021